SXI Life Sciences
7.139,76
PKT
+102,44
PKT
+1,46
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
25.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
24.04.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
24.04.19 | Novartis Neutral | UBS AG | |
24.04.19 | Alcon buy | Goldman Sachs Group Inc. | |
24.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
18.04.19 | Alcon Market Perform | BMO Capital Markets | |
18.04.19 | Roche buy | Jefferies & Company Inc. | |
18.04.19 | Roche Neutral | Credit Suisse Group | |
18.04.19 | Roche Hold | Deutsche Bank AG | |
17.04.19 | Roche buy | Goldman Sachs Group Inc. | |
17.04.19 | Roche Hold | Kepler Cheuvreux | |
17.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
17.04.19 | Roche Neutral | UBS AG | |
17.04.19 | Roche buy | Goldman Sachs Group Inc. | |
17.04.19 | Novartis buy | Jefferies & Company Inc. | |
16.04.19 | Novartis buy | Kepler Cheuvreux | |
12.04.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
11.04.19 | Roche buy | Goldman Sachs Group Inc. | |
10.04.19 | Alcon Neutral | UBS AG | |
10.04.19 | Novartis Underweight | Barclays Capital | |
10.04.19 | Novartis Underweight | Morgan Stanley | |
08.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
08.04.19 | Novartis Underweight | Barclays Capital | |
05.04.19 | Novartis Neutral | Credit Suisse Group | |
05.04.19 | Roche Hold | Deutsche Bank AG | |
05.04.19 | Novartis Hold | Deutsche Bank AG | |
03.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
03.04.19 | Roche overweight | JP Morgan Chase & Co. | |
02.04.19 | Roche overweight | JP Morgan Chase & Co. | |
29.03.19 | Roche overweight | JP Morgan Chase & Co. | |
27.03.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
27.03.19 | Novartis buy | Jefferies & Company Inc. | |
25.03.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
19.03.19 | Roche overweight | Barclays Capital | |
14.03.19 | Roche buy | Jefferies & Company Inc. | |
04.03.19 | Novartis Neutral | UBS AG | |
04.03.19 | Roche Neutral | UBS AG | |
26.02.19 | Roche Hold | Deutsche Bank AG | |
26.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
25.02.19 | Roche Neutral | Credit Suisse Group |